These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 26071795)

  • 101. Assessment of early treatment response to neoadjuvant chemotherapy in breast cancer using non-mono-exponential diffusion models: a feasibility study comparing the baseline and mid-treatment MRI examinations.
    Bedair R; Priest AN; Patterson AJ; McLean MA; Graves MJ; Manavaki R; Gill AB; Abeyakoon O; Griffiths JR; Gilbert FJ
    Eur Radiol; 2017 Jul; 27(7):2726-2736. PubMed ID: 27798751
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Neoadjuvant combination for stage II-III breast cancer.
    Bagchi S
    Lancet Oncol; 2007 Jul; 8(7):579. PubMed ID: 17668486
    [No Abstract]   [Full Text] [Related]  

  • 103. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 104. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
    Sjöström J; Collan J; von Boguslawski K; Franssila K; Bengtsson NO; Mjaaland I; Malmström P; Østenstad B; Wist E; Valvere V; Bergh J; Skiöld-Petterson D; Saksela E; Blomqvist C
    Eur J Cancer; 2002 Mar; 38(4):535-42. PubMed ID: 11872346
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography.
    Burcombe RJ; Makris A; Pittam M; Lowe J; Emmott J; Wong WL
    Eur J Cancer; 2002 Feb; 38(3):375-9. PubMed ID: 11818202
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case-control study.
    Tsai JH; Li CL; Yeh DC; Hung CS; Hung CC; Lin CY; Kuo YL
    Breast Cancer Res Treat; 2023 May; 199(1):47-55. PubMed ID: 36869992
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.
    Michlmayr A; Bachleitner-Hofmann T; Baumann S; Marchetti-Deschmann M; Rech-Weichselbraun I; Burghuber C; Pluschnig U; Bartsch R; Graf A; Greil R; Allmaier G; Steger G; Gnant M; Bergmann M; Oehler R
    Br J Cancer; 2010 Oct; 103(8):1201-8. PubMed ID: 20877360
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins.
    Asakawa H; Koizumi H; Koike A; Takahashi M; Wu W; Iwase H; Fukuda M; Ohta T
    Breast Cancer Res; 2010; 12(2):R17. PubMed ID: 20205718
    [TBL] [Abstract][Full Text] [Related]  

  • 109. DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Li XR; Cheng LQ; Liu M; Zhang YJ; Wang JD; Zhang AL; Song X; Li J; Zheng YQ; Liu L
    Med Oncol; 2012 Jun; 29(2):425-31. PubMed ID: 21286861
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy.
    Roubidoux MA; LeCarpentier GL; Fowlkes JB; Bartz B; Pai D; Gordon SP; Schott AF; Johnson TD; Carson PL
    J Ultrasound Med; 2005 Jul; 24(7):885-95. PubMed ID: 15972702
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.
    Ali HR; Dariush A; Thomas J; Provenzano E; Dunn J; Hiller L; Vallier AL; Abraham J; Piper T; Bartlett JMS; Cameron DA; Hayward L; Brenton JD; Pharoah PDP; Irwin MJ; Walton NA; Earl HM; Caldas C
    Ann Oncol; 2017 Aug; 28(8):1832-1835. PubMed ID: 28525534
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Correlation between magnetic resonance imaging and histopathological tumor response after neoadjuvant chemotherapy in breast cancer.
    Nicoletto MO; Nitti D; Pescarini L; Corbetti F; Mencarelli R; Cappetta A; Galligioni A; Pogliani C; Marchet A; Bozza F; Ghiotto C; Griggio L; Zavagno G; Donach ME; Di Maggio C
    Tumori; 2008; 94(4):481-8. PubMed ID: 18822682
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Is pathological complete response predictable after neoadjuvant chemotherapy in breast cancer? A single institution's retrospective experience.
    Winder AA; Dijkstra B
    ANZ J Surg; 2021 Sep; 91(9):1779-1783. PubMed ID: 34056804
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?
    Lo SS; Wang HC; Shyr YM; Lui WY
    J Surg Oncol; 1994 Oct; 57(2):94-6. PubMed ID: 7934069
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.
    Kim SY; Cho N; Shin SU; Lee HB; Han W; Park IA; Kwon BR; Kim SY; Lee SH; Chang JM; Moon WK
    Eur Radiol; 2018 Jul; 28(7):2986-2995. PubMed ID: 29380033
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Effect of neoadjuvant chemotherapy on breast tissue composition: a longitudinal mammographic study with automated volumetric measurement.
    Jang HJ; Kim HJ; Chae YS; Lee SJ; Kim SH; Lee H; Kim WH
    Eur Radiol; 2020 Sep; 30(9):4785-4794. PubMed ID: 32314056
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: a single-center experience.
    Mermut O; Inanc B; Gursu RU; Arslan E; Trabulus DC; Havare SB; Ulusan MB
    Rev Assoc Med Bras (1992); 2021 Jun; 67(6):845-850. PubMed ID: 34709328
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer.
    Ahn JH; Go J; Lee SJ; Kim JY; Park HS; Kim SI; Park BW; Park VY; Yoon JH; Kim MJ; Park S
    Korean J Radiol; 2023 May; 24(5):384-394. PubMed ID: 37133209
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
    Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
    Tumour Biol; 2013 Feb; 34(1):81-90. PubMed ID: 22983919
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Elevated Sera IL-6 and NK-T Cells Associated With Increased Pathological Complete Response in HER2-positive Breast Cancer With Carboplatin-based Neoadjuvant Therapy.
    Wang L; Zhang X; Ma X; Ren X; Ma X; Shan B; Liu Y
    Altern Ther Health Med; 2023 Apr; 29(3):246-253. PubMed ID: 36881538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.